<DOC>
	<DOCNO>NCT02277392</DOCNO>
	<brief_summary>This phase-I , dose escalation study assess safety biological activity cyclophosphamide/fludarabine lymphodepletion follow adoptive transfer vaccine-primed , ex vivo CD3/CD28-costimulated peripheral blood autologous T-cells , recombinant human interleukin-18 ( SB-485232 , IL-18 ) treatment adult patient recurrent , Stage III IV ovarian cancer , fallopian tube primary peritoneal cancer previously underwent induction vaccination whole tumor vaccine</brief_summary>
	<brief_title>A Phase-I , Dose Escalation Study Recombinant Human Interleukin-18 ( Sb-485232 ) Combined With Adoptive Transfer Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion Adult Patients With Recurrent Ovarian , Fallopian Tube Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Female great equal 18 year age . Histologically confirm diagnosis epithelial cancer . Subject must measurable disease enrollment consideration Subjects receive least one vaccine protocol UPCC19809 UPCC29810 Predicted life expectancy great equal 4 month . ECOG performance status 0 1 . Must least 4 week postoperative No chemotherapy , immunotherapy , hormonal therapy , biological therapy cancer , radiotherapy , surgical procedure ( except minor surgical procedure ) within four week begin treatment SB485232 ( six week nitrosoureas mitomycin C ) . Subjects must recover toxicity ( incur result previous therapy ) sufficiently enter Phase I study . Blood coagulation parameter : PT international normalize ratio ( INR ) less equal 1.5 ( inrange INR , usually 2 3 , subject stable dose therapeutic warfarin anticoagulant management venous thrombosis include pulmonary thromboembolus ) PTT le 1.5 time upper limit normal . A signed date write informed consent form obtain subject . The subject able understand comply protocol requirement , timetable , instruction protocolstated restriction . Normal organ bone marrow function define : Absolute neutrophil count great 1,000/ul Platelets great 100,000/ul Hematocrit great equal 30 percent AST ( SGOT ) /ALT ( SGPT ) less 2.5 X institutional upper limit normal Bilirubin le 2.0 mg/dL unless secondary bile duct blockage tumor Creatinine le than1.8 mg/dL Significant cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal autoimmune condition opinion investigator place subject unacceptable risk participant trial . Subjects severe concurrent disease condition , include significant active autoimmune disease rheumatoid arthritis , judgment principal investigator would make subject inappropriate study participation . Subjects require likely require twoweek course corticosteroid intercurrent illness . Subjects must complete therapy prior enrollment . Topical corticosteroid stop least 2 week prior enrollment systemic corticosteroid stop least 4 week prior enrollment . Subjects acute infection severe uncontrolled require systematic antibiotic therapy . Acute therapy must complete least seven day prior study enrollment . Subjects underlying condition , would contraindicate therapy , study treatment ( allergies reagent use study ) . Women pregnant breastfeeding . Subject positive test result screen visit one following : HTLV1/2 and/or AntiHIV 1 Antibody ( aHIV1 ) . Subjects receive medication might affect immune function . Additionally , H2 blocker exclude , antihistamine five day five day injection study drug . NOTE : The following exception : Proton pump Inhibitors ( PPIs ) , NSAIDS include COX2 inhibitor , acetaminophen Enteric Coated Aspirin . Subjects positive serum antiYo ( cdr2 ) antibody eligible ( Yo antibody need repeat perform past ) . Subjects receive class III antiarrythmic medication . Subjects serious medical psychiatric disorder would interfere subject safety inform consent . Psychological , familial , sociological , geographical condition permit compliance protocol . Known leptomeningeal disease evidence prior current metastatic brain disease . Any investigational drug within 30 day five halflives ( whichever longer ) precede first dose SB485232 . Subject measurable disease . Subject tissue UPCC19809 EOS biopsy unwilling undergo screen biopsy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>